GlobeNewswire·Oct 7, 2025, 8:00 AM ET

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

MeiraGTx Holdings plc (NASDAQ: MGTX) will present two posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress in Seville, Spain, running from October 7-10, 2025.
Poster P0089 details the development of novel AAV capsids for intravitreal delivery using directed evolution in non-human primate eyes, validated in human retinal organoids.
The P0089 research identified top-performing capsids from a library of ~1E7 variants that demonstrated over 2-fold higher transduction efficiency compared to AAV2.7m8 in human retinal organoids.
Additional validation in human iPSC-derived RPE cells and in vivo mouse studies confirmed that the novel capsids achieved higher overall retinal expression levels than AAV2.7m8.
Poster P0170 outlines the scale-up of a perfusion-based AAV manufacturing process to 40L bioreactors, building on bench-scale optimization that increased volumetric yield by 120% and reduced plasmid DNA usage by 50%.
The scaled perfusion process aims to reduce the cost-of-goods per dose by up to 2.2-fold while maintaining product quality for clinical and commercial use.
MeiraGTx is a clinical-stage genetic medicines company with four late-stage programs targeting ocular diseases, Parkinson's disease, and radiation-induced xerostomia.
The company operates five global manufacturing facilities, including two licensed for GMP viral vector production, and utilizes a proprietary riboswitch gene regulation technology for oral delivery of biologic therapeutics.